Is cabergoline a better drug to inhibit lactation in patients with psychotic symptoms?

Journal of Psychiatry and Neuroscience

Volumn 27, Issue 1, 2002, Pages 54-

  Baeza Pertegaz, Inmaculada ^a   Goikolea Alberdi, José Manuel ^a   Parellada Rodón, Eduard ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; HALOPERIDOL; RISPERIDONE;

ACROMEGALY; AMENORRHEA; CASE REPORT; DROWSINESS; DRUG CHOICE; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG TOLERABILITY; GALACTORRHEA; HEADACHE; HUMAN; LACTATION INHIBITION; LETTER; NAUSEA; PARKINSON DISEASE; PROLACTIN RELEASE; PROLACTINOMA; PSYCHOSIS; PUERPERAL PSYCHOSIS;

DEPRESSION, POSTPARTUM; DOPAMINE AGONISTS; ERGOLINES; FEMALE; HUMANS; LACTATION; PSYCHOTIC DISORDERS;

EID: 0036246008     PISSN: 11804882     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (9)

1. A comparative review of the tolerability profiles of dopamine agonists in the treatment of hyperprolactinaemia and inhibition of lactation
2. Bromocriptine and psychosis: A literature review
3. Postpartum psychosis induced by bromocriptine and pseudoephedrine
4. Mental disorders from low-dose bromocriptine
5. Cabergoline. A review of its pharmacological properties and therapeutic potential in treatment of hyperprolactinaemia and inhibition of lactation
6. Cabergoline
7. Prolactin lowering effect of a new ergoline derivative, FCE 21336, in the rat: A comparison with bromocriptine
8. Inhibition of basal and metoclopramide-induced prolactin release by cabergoline, an extremely long-acting dopaminergic drug
9. 3 receptors: Effects of MPTP and dopamine agonist replacement therapies